Samantha Wenzel
Acute Care · Boynton Beach, FLNPI 1942727979
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,693 of the $6,487 with a category attached, or 87.8%. It is spread thinly across 33 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. Among acute care clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 276 payments — averaging $23.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$1K
- Akcea Therapeutics, Inc.$576
- E.r. Squibb & Sons, L.L.C.$511
- AstraZeneca$426
- Novartis$372
- Merck$353
- plus $3K from 27 others
What the payments were for
- Consulting fees$5609%
- Food & beverage$5,69388%
- Education$2344%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 34 | $1,157 |
| Akcea Therapeutics, Inc. | 2 | $576 |
| E.r. Squibb & Sons, L.L.C. | 18 | $511 |
| AstraZeneca | 23 | $426 |
| Novartis | 19 | $372 |
| Merck | 18 | $353 |
| Pfizer | 15 | $310 |
| Edwards Lifesciences | 4 | $276 |
| Boehringer Ingelheim | 12 | $273 |
| Cvrx, Inc. | 26 | $270 |
| Alnylam Pharmaceuticals Inc. | 12 | $241 |
| Amgen | 19 | $213 |
| Johnson & Johnson | 8 | $142 |
| Bridgebio Pharma, Inc. | 7 | $133 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $132 |
| Novo Nordisk | 4 | $126 |
| Bayer | 6 | $125 |
| Boston Scientific | 6 | $120 |
| United Therapeutics Corporation | 4 | $105 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $96 |
| Abiomed | 5 | $89 |
| Sanofi-aventis U.S. LLC | 3 | $71 |
| Agepha Pharma FZ LLC | 3 | $59 |
| Medtronic | 2 | $47 |
| Kowa Pharmaceuticals America, Inc. | 2 | $40 |
| Lexicon Pharmaceuticals, Inc. | 2 | $39 |
| Stryker | 1 | $36 |
| Esperion Therapeutics, Inc. | 2 | $35 |
| AbbVie(2 entities) | 2 | $29 |
| Inari Medical, Inc. | 1 | $29 |
| Biotronik Inc. | 1 | $22 |
| CSL Behring | 1 | $19 |
| Kestra Medical Technology Services, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,487 in reported general payments places this provider in the 95th percentile of 1,150 acute care providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CamzyosMavacamten | 20 | $159,845 |
| EliquisApixaban | 76 | $89,447 |
| XareltoRivaroxaban | 64 | $80,295 |
| EntrestoSacubitril/Valsartan | 25 | $36,282 |
| BrilintaTicagrelor | 46 | $35,354 |
| MultaqDronedarone Hcl | 13 | $28,795 |
| FarxigaDapagliflozin Propanediol | 13 | $16,266 |
| Metoprolol Succinate | 161 | $2,705 |
| Valsartan | 74 | $2,468 |
| Ranolazine ErRanolazine | 14 | $2,037 |
| Losartan Potassium | 106 | $1,076 |
| Atorvastatin Calcium | 100 | $990 |
| Rosuvastatin Calcium | 60 | $886 |
| Nifedipine ErNifedipine | 42 | $864 |
| ClopidogrelClopidogrel Bisulfate | 62 | $782 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Camzyos | $511 | $159,84520 claims |
| PfizerEliquis | $310 | $89,44776 claims |
| Johnson & JohnsonXarelto | $142 | $80,29564 claims |
| AstraZenecaBrilinta, Farxiga | $426 | $51,62059 claims |
| NovartisEntresto | $372 | $36,28225 claims |
| Sanofi-aventis U.S. LLCMultaq | $71 | $28,79513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,150 acute care providers in Florida.
Other acute care in Boynton Beach
- Melisa WilsonOrlando$214K
- Amanda PeacockJacksonville$81K
- Katrina RileyTampa$66K
- Diane GrayLake Mary$49K
- Heather RamousSafety Harbor$38K
- Melanie WeresJacksonville$37K
- Jayne JaramilloJacksonville$27K
- Melissa HamiltonTampa$23K
- Kimberly GrantAltamonte Springs$20K
- Julie ElliottWinter Haven$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.